Table 1. Demographic and clinical characteristics of moderate patients with COVID-19
| Â | Total (n = 1681) | Length of hospital stays | p-value | |
|---|---|---|---|---|
Short-stay (≤ 13 days) (n = 892) | Long-stay (> 13 days) (n = 789) | |||
Age (years) | 58 (48,67) | 56 (46, 65) | 61 (50, 68) | <0.001 |
 ≥ 60 | 786 (46.8%) | 370 (41.5%) | 416 (52.7%) | <0.001 |
Gender | ||||
 Male | 836 (49.7%) | 441 (49.4%) | 395 (50.1%) | 0.799 |
 Female | 845 (50.3%) | 451 (50.6%) | 394 (49.9%) |  |
History of smoking | ||||
 Yes | 115/1662 (6.9%) | 66/885 (7.5%) | 49/777 (6.3%) | 0.356 |
Clinical symptoms | ||||
 Cough | 1182 (70.3%) | 584 (65.5%) | 598 (75.8%) | <0.001 |
 Fever | 1216 (72.3%) | 585 (65.6%) | 631 (80.0%) | <0.001 |
 Asthma or dyspnea | 702 (41.8%) | 311 (34.9%) | 391 (49.6%) | <0.001 |
 Fatigue | 898 (53.4%) | 430 (48.2%) | 468 (59.3%) | <0.001 |
 Myalgia | 500 (29.7%) | 217 (24.3%) | 283 (35.9%) | <0.001 |
 Other features | 464 (27.6%) | 235 (26.3%) | 229 (29.0%) | 0.220 |
Clinical outcome | ||||
 Discharge | 1675 (99.6%) | 890 (99.8%) | 785 (99.5%) | 0.332 |
 Died | 6 (0.4%) | 2 (0.2%) | 4 (0.5%) |  |
Number of symptoms | 3 (2, 4) | 3 (2, 4) | 3 (2, 5) | <0.001 |
 > 3 | 644 (38.3%) | 272 (30.5%) | 372 (47.1%) | <0.001 |
Maximum body temperature ≥ 37.3 ℃ | 502/1664 (30.2%) | 167/884 (18.9%) | 335/780 (42.9%) | <0.001 |
Comorbidity | ||||
 Hypertension | 467/1672 (27.9%) | 240/891 (26.9%) | 227/781 (29.1%) | 0.333 |
 Diabetes | 214/1672 (12.8%) | 109/891 (12.2%) | 105/781 (13.4%) | 0.460 |
 Other cardiovascular disease | 159/1672 (9.5%) | 86/891 (9.7%) | 73/781 (9.3%) | 0.832 |
 Respiratory disease | 84/1672 (5.0%) | 51/891 (5.7%) | 33/781 (4.2%) | 0.162 |
 Other disease | 243/1672 (14.5%) | 118/891 (13.2%) | 125/781 (16.0%) | 0.110 |
Imaging features | ||||
Position | ||||
 Bilateral pulmonary | 1375/1512 (90.9%) | 699/791 (88.4%) | 676/721 (93.8%) | <0.001 |
Density | ||||
 mGGO | 1269/1487 (85.3%) | 643/749 (85.8%) | 626/738 (84.8%) | 0.577 |
Therapy | ||||
 Antibiotics | 441/1670 (26.4%) | 149/887 (16.8%) | 292/783 (37.3%) | <0.001 |
 Antiviral | 776/1674 (46.4%) | 288/890 (32.4%) | 488/784 (62.2%) | <0.001 |
 Corticosteroids | 105/1652 (6.4%) | 16/884 (1.8%) | 89/768 (11.6%) | <0.001 |
 Traditional Chinese medicine treatment | 1522/1669 (91.2%) | 771/888 (86.8%) | 751/781 (96.2%) | <0.001 |
Oxygen therapy | 998/1641 (60.8%) | 475/881 (53.9%) | 523/760 (68.8%) | <0.001 |
Other therapy | 109/1622 (6.7%) | 32/871 (3.7%) | 77/751 (10.3%) | <0.001 |
Laboratory findings | ||||
 Leucocyte count, ×109 per L | 5.60 (4.70, 6.80) | 5.60 (4.80, 6.80) | 5.50 (4.50, 6.90) | 0.103 |
 Lymphocyte count, ×109 per L | 1.56 (1.19, 1.92) | 1.65 (1.30, 2.02) | 1.43 (1.07, 1.81) | <0.001 |
 Hemoglobin, g/L | 125 (115, 136) | 127 (116, 136) | 123 (114, 134) | <0.001 |
 Platelet count, × 109 per L | 226 (186, 279) | 215 (181, 261) | 241 (193, 305) | <0.001 |
 NLR | 2.18 (1.62, 3.01) | 2.02 (1.58, 2.73) | 2.39 (1.69, 3.42) | <0.001 |
 CRP, mg/L | 1.71 (0.68, 5.12) | 1.22 (0.55, 3.03) | 2.68 (0.91, 9.31) | <0.001 |
 ALT, U/L | 23.40 (14.60, 38.70) | 21.20 (14.10, 33.78) | 25.95 (15.80, 42.70) | <0.001 |
 Albumin, g/L | 38.30 (35.60, 40.63) | 39.40 (36.90, 41.50) | 36.90 (34.10, 39.50) | <0.001 |
 BUN, mmol/L | 4.32 (3.59, 5.22) | 4.34 (3.61, 5.33) | 4.27 (3.59, 5.15) | 0.203 |
 Creatinine, umol/L | 64.00 (55.00,74.90) | 63.90 (54.90, 75.00) | 64.10 (55.00, 74.50) | 0.941 |
 Creatine kinase, U/L | 50.10 (36.00, 71.25) | 53.75 (38.85, 72.50) | 45.20 (32.40, 67.40) | <0.001 |
 LDH, U/L | 170.30 (148.50, 201.20) | 161.60 (142.50, 186.70) | 185.20 (159.45, 228.95) | <0.001 |
 Prothrombin time, s | 12.72 (12.18, 13.40) | 12.74 (12.23, 13.40) | 12.71 (12.13, 13.40) | 0.756 |
 D-dimer, ug/L | 0.35 (0.18, 0.64) | 0.30 (0.17, 0.56) | 0.41 (0.23, 0.82) | <0.001 |